Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iMSC-derived extracellular vesicles (iMSC-EVs) are nanoscale, lipid-bilayer vesicles secreted by mesenchymal stem cells that have been differentiated from induced pluripotent stem cells (iMSCs). These vesicles contain a complex mixture of proteins, lipids, mRNAs, and microRNAs, and they function to transfer biological signals between cells. iMSC-EVs are being investigated as a promising cell-free therapeutic modality, leveraging the regenerative and immunomodulatory potential of MSCs without the risks of live-cell therapies. Their mechanisms of action include the modulation of immune cell activity (such as downregulating pro-inflammatory cytokines and altering T cell and innate lymphoid cell responses), promotion of tissue repair and regeneration, and anti-fibrotic effects in several organ systems. Preclinical studies support their application in conditions such as tendinopathy, asthma, liver injury, renal fibrosis, and wound healing. They are a focus of ongoing research in regenerative medicine and immunotherapy, though not yet approved for clinical use[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iMSC-derived extracellular vesicles.